Published by Benjamin Chiou on 11th June 2024
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.
URL: http://www.digitallook.com/dl/news/story/34353960/...